Bind raises $11 million

Bind Biosciences Inc. (Cambridge, Mass.) raised $11 million in a series C round led by new investor DHK Investment. Other undisclosed new investors participated along with all existing investors, including Polaris Venture Partners; Flagship Ventures; Arch Venture Partners; and NanoDimension. Bind's lead candidate, BIND-014, is expected to begin Phase I testing next half to treat solid tumors. BIND-014 is a nanoparticle containing docetaxel that concentrates in the neovasculature surrounding tumors and targets prostate-specific membrane antigen (PSMA). Taxotere docetaxel is marketed by sanofi-aventis Group (Euronext:SAN; NYSE:SNY). ...